Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to seven new employees on June 2, 2025. The awards consist of non-qualified share options to purchase 57,700 ordinary shares under the company's 2024 Inducement Plan. The options have an exercise price of $8.22 per share, based on the company's closing price on May 30, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment. These grants were approved by the Compensation Committee as inducement material for new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicycle Therapeutics (NASDAQ: BCYC) announced two poster presentations at the upcoming 2025 ASCO Annual Meeting in Chicago from May 30-June 3. The first presentation will share preliminary results from the Phase 1/2 Duravelo-1 study of zelenectide pevedotin (BT8009) combined with pembrolizumab in treating previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. The second poster will present a phase 2/3 study (Duravelo-2) of BT8009 targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer. Both presentations are scheduled for Monday, June 2, and will be available on the company's website.

Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to 13 new employees on May 1, 2025. The awards consist of non-qualified share options to purchase a total of 79,500 ordinary shares at an exercise price of $8.56 per share, which was the company's closing price on April 30, 2025.

The options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months. These grants were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicycle Therapeutics (NASDAQ: BCYC) reported Q1 2025 financial results and business updates. The company ended Q1 with $793.0 million in cash, providing runway into 2H 2027. Key highlights include: multiple abstracts accepted at ASCO and AACR meetings, ongoing recruitment for Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer, and new leadership appointments. Financial results show R&D expenses increased to $59.1 million (up from $34.9M in Q1 2024), while net loss widened to $60.8 million ($0.88 per share). The company continues to advance its oncology pipeline, with dose selection for the Phase 2/3 Duravelo-2 trial in metastatic urothelial cancer expected in 2H 2025. Additionally, promising MT1-MMP imaging data was presented at AACR, validating their Bicycle® Radioconjugate technology.

Bicycle Therapeutics presented additional human imaging data for their MT1-MMP targeting Bicycle® Radioconjugates (BRC®) at AACR 2025. The data, representing 12 patients with various solid tumors, validates MT1-MMP as a promising cancer target.

Key findings include successful imaging results from two patients:

• A 65-year-old male with advanced lung cancer showed BRC tracer uptake in primary tumor, lymph nodes, and bones
• An 84-year-old female with breast and bladder cancer demonstrated higher BRC tracer uptake in primary tumors compared to conventional imaging

The company reports positive outcomes in 12 out of 14 patients tested across various cancers. Looking ahead, Bicycle Therapeutics expects to share initial human imaging data for their second target EphA2 in late 2025, with company-sponsored radiopharmaceutical trials planned for 2026.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on April 1, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase a total of 32,400 ordinary shares.

The options were granted at an exercise price of $8.49 per share, matching Bicycle's closing trading price on March 31, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.

Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide (Bicycle®) technology, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, at 12:45 p.m. ET.

Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). The company will also make a replay of the webcast available for viewing after the event.

Bicycle Therapeutics (NASDAQ: BCYC) announced significant leadership changes to strengthen its oncology expertise. Felix J. Baker, Ph.D., will become chairman of the Board of Directors, succeeding Pierre Legault who will retire after the Annual General Meeting in June 2025. Alessandro Riva, M.D., joins the Board of Directors, while Fabrice André, M.D., Ph.D., joins the Clinical Advisory Board.

The company also announced internal promotions, with Eric Westin, M.D., elevated to chief medical officer and Jim MacDonald-Clink promoted to senior vice president, head of business development. These appointments follow the transitions of Santiago Arroyo and Nigel Crockett to advisor roles as distinguished fellows.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on March 3, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase 73,700 ordinary shares.

The options have an exercise price of $10.97 per share, matching Bicycle's closing price on February 28, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).